Type of non Hodgkin's lymphoma-Other-Primary mediastinal large B-cell lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Other-Primary mediastinal large B-cell lymphoma Posts on Medivizor

Evaluating the effectiveness and safety of polatuzumab vedotin combined with dose-adjusted EPOCH-R chemotherapy in patients with aggressive B-cell non-Hodgkin lymphoma.

Evaluating the effectiveness and safety of polatuzumab vedotin combined with dose-adjusted EPOCH-R chemotherapy in patients with aggressive B-cell non-Hodgkin lymphoma.

Posted by on Jul 30, 2023 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of polatuzumab vedotin (PV; Polivy) combined with dose-adjusted EPOCH-R chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL). The data showed that PV combined with dose-adjusted EPOCH-R...

Read More

Evaluating the effectiveness and safety of venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma.

Evaluating the effectiveness and safety of venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma.

Posted by on Sep 18, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding venetoclax (Venclexta) to a dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) regimen as initial therapy in patients with aggressive B-cell lymphoma. The data showed that venetoclax with dose-adjusted EPOCH-R was effective...

Read More

Evaluating bendamustine with ofatumumab, carboplatin and etoposide for relapsed/refractory aggressive non-Hodgkin lymphoma

Evaluating bendamustine with ofatumumab, carboplatin and etoposide for relapsed/refractory aggressive non-Hodgkin lymphoma

Posted by on Dec 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the combination of bendamustine (Treanda), ofatumumab (Arzerra), carboplatin (Paraplatin), and etoposide (Etopophos) in patients with relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).   This study concluded that this combination was safe and effective in these...

Read More

How the characteristics of CAR-T cell infusion products impact their effectiveness and toxicity in patients with large B cell lymphomas

How the characteristics of CAR-T cell infusion products impact their effectiveness and toxicity in patients with large B cell lymphomas

Posted by on Oct 18, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated how characteristics of CAR-T cell infusion (CTCI) products impact their effectiveness and toxicity in patients with large B cell lymphoma (LBCL). The authors found that diversity in molecular and cellular features of CTCI products caused variations in efficacy and toxicity after axicabtagene-ciloleucel (axi-cel;...

Read More

Axicabtagene ciloleucel for aggressive B-cell lymphoma outside clinical trials

Axicabtagene ciloleucel for aggressive B-cell lymphoma outside clinical trials

Posted by on Jul 28, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at axicabtagene ciloleucel (Yescarta) to treat B-cell non-Hodgkin lymphoma which has returned after previous treatment outside of clinical trials. It found that most patients responded to this immune therapy and that some patients had a complete response. Some background B-cell non-Hodgkin lymphomas (NHL) are a group of...

Read More

How effective is a modified anti-nausea and vomiting treatment for patients with non-Hodgkin lymphoma undergoing chemotherapy?

How effective is a modified anti-nausea and vomiting treatment for patients with non-Hodgkin lymphoma undergoing chemotherapy?

Posted by on May 17, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effectiveness of a modified anti-nausea and vomiting treatment for patients with aggressive non-Hodgkin lymphoma (NHL) receiving high-dose (HD) chemotherapy. The results showed that netupitant/palonosetron (NEPA; Akynzeo) alone was very effective and safe for these patients. Some background Chemotherapy...

Read More

Evaluating the safety and effectiveness of the Shingrix vaccine for patients with lymphoma or leukemia

Evaluating the safety and effectiveness of the Shingrix vaccine for patients with lymphoma or leukemia

Posted by on Aug 23, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the herpes zoster vaccine (Shingrix) in patients with blood cancer who are receiving anti-cancer therapy. This study concluded that the Shingrix vaccine was effective in these patients, with manageable side effects. Some background Shingles is caused by a virus called herpes zoster....

Read More

Evaluating nivolumab plus brentuximab vedotin for patients with relapsed or unresponsive primary mediastinal large B-cell lymphoma

Evaluating nivolumab plus brentuximab vedotin for patients with relapsed or unresponsive primary mediastinal large B-cell lymphoma

Posted by on Aug 17, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....

Read More

Searching for patients with relapsed or unresponsive non-Hodgkin lymphoma to try a new cell therapy

Posted by on Jun 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This Phase 2 study is evaluating the safety and effectiveness of a new T-cell therapy for B-cell non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. The main outcomes to be measured will be the number of patients who experience side effects and overall response after treatment. This trial is recruiting...

Read More

Evaluating chemoimmunotherapy for children with aggressive B-cell lymphoma

Evaluating chemoimmunotherapy for children with aggressive B-cell lymphoma

Posted by on May 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of chemoimmunotherapy in children and adolescents with aggressive B-cell non-Hodgkin’s lymphoma (NHL). This study concluded that combined chemoimmunotherapy is highly effective in these young patients. Some background B-cell NHL is one of the most common types of lymphoma in children and...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor